Phio Pharmaceuticals Corp
PHIO
查看详细走势图
0.920USD
+0.063+7.39%
收盘 02/06, 16:00（美东）报价延迟15分钟
5.32M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+7.39%
5天
-8.90%
1月
-23.96%
6月
-59.11%
今年开始到现在
-12.37%
1年
-51.32%
查看详细走势图
TradingKey Phio Pharmaceuticals Corp股票评分
单位: USD 更新时间: 2026-02-06操作建议
Phio Pharmaceuticals Corp当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名170/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价14.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Phio Pharmaceuticals Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Phio Pharmaceuticals Corp亮点
亮点风险
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
分析师目标
根据
1
位分析师
买入
评级
14.000
目标均价
+1413.51%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Phio Pharmaceuticals Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Phio Pharmaceuticals Corp简介
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
公司代码PHIO
公司Phio Pharmaceuticals Corp
CEOBitterman (Robert J)
网址https://phiopharma.com/
相关品种
